Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.

about

Pharmacology and pharmacokinetics of imatinib in pediatric patients.Optimal management for pediatric chronic myeloid leukemia.

P2860

Q50094239-BD394D43-6991-4EAB-91C0-1B6FC816931A Q55034870-D909FDF9-5C22-4A44-86E2-2089DF382038

P2860

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q54354157

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Sustained complete molecular r ...... with chronic myeloid leukemia.

@en

Sustained complete molecular r ...... with chronic myeloid leukemia.

@nl

type

Item

label

Sustained complete molecular r ...... with chronic myeloid leukemia.

@en

Sustained complete molecular r ...... with chronic myeloid leukemia.

@nl

prefLabel

Sustained complete molecular r ...... with chronic myeloid leukemia.

@en

Sustained complete molecular r ...... with chronic myeloid leukemia.

@nl

P1476

Sustained complete molecular r ...... with chronic myeloid leukemia

@en

P2093

Dagmar Dilloo

http://www.w3.org/2001/XMLSchema#string

Indra Janz

http://www.w3.org/2001/XMLSchema#string

Josephine T Tauer

http://www.w3.org/2001/XMLSchema#string

Manuela Krumbholz

http://www.w3.org/2001/XMLSchema#string

Meinolf Suttorp

http://www.w3.org/2001/XMLSchema#string

Melchior Lauten

http://www.w3.org/2001/XMLSchema#string

Olga Moser

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.

Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Dysregulation of bone remodeling by imatinib mesylate.

Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation.

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

P304

2080-2082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.25090

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Thiede

Markus Metzler

P577

2014-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24810322

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.

about

P2860

P2860

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921